Literature DB >> 26440099

[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman].

H Fey1, M Jost2, A T Geise2, T Bertsch3, M Christ2.   

Abstract

β-Blockers and calcium channel blockers are commonly used drugs in the treatment of atrial fibrillation with tachycardia. However, in patients with high myocardial susceptibility and vulnerability, combination therapy with β-blockers and non-dihydropyridine calcium channel blockers (verapamil or diltiazem) but also individual administration can cause drug-induced cardiogenic shock. Thus, the simultaneous administration of β-blockers and non-dihydropyridine calcium channel blockers is absolutely contraindicated. In case of acute heart failure, isolated application is also contraindicated. In the treatment of a cardiogenic shock induced by β-blockers and/or non-dihydropyridine calcium channel blockers, administration of intravenous calcium, glucagon or high-dose insulin is recommended.

Entities:  

Keywords:  Beta-blockers, adrenergic; Calcium channel blockers; Cardiac dysrhythmia; Glucagon; Tachycardia

Mesh:

Substances:

Year:  2015        PMID: 26440099     DOI: 10.1007/s00063-015-0089-9

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  19 in total

1.  Cardiogenic shock secondary to combination of diltiazem and sotalol.

Authors:  H Yorgun; A Deniz; K Aytemir
Journal:  Intern Med J       Date:  2008-03       Impact factor: 2.048

Review 2.  [Antidotes in clinical toxicology].

Authors:  K Hruby
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-08-08       Impact factor: 0.840

Review 3.  High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning.

Authors:  Kristin M Engebretsen; Kathleen M Kaczmarek; Jenifer Morgan; Joel S Holger
Journal:  Clin Toxicol (Phila)       Date:  2011-04       Impact factor: 4.467

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Electromechanical dissociation following verapamil and propranolol ingestion: a physiologic profile.

Authors:  A B Waxman; K P White; D R Trawick
Journal:  Cardiology       Date:  1997 Sep-Oct       Impact factor: 1.869

6.  Regulation of Ca2+ influx in myocardial cells by beta adrenergic receptors, cyclic nucleotides, and phosphorylation.

Authors:  N Sperelakis; G M Wahler
Journal:  Mol Cell Biochem       Date:  1988 Jul-Aug       Impact factor: 3.396

7.  Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.

Authors:  M Henry; M M Kay; P Viccellio
Journal:  Am J Emerg Med       Date:  1985-07       Impact factor: 2.469

Review 8.  Molecular basis of calcium channel blockade.

Authors:  A M Katz
Journal:  Am J Cardiol       Date:  1992-04-30       Impact factor: 2.778

9.  High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and Beta-blocker overdose: a case series.

Authors:  Bruce Doepker; William Healy; Eric Cortez; Eric J Adkins
Journal:  J Emerg Med       Date:  2014-02-13       Impact factor: 1.484

10.  Hypotension and sinus arrest with exercise-induced hyperkalemia and combined verapamil/propranolol therapy.

Authors:  T H Lee; D R Salomon; C M Rayment; E M Antman
Journal:  Am J Med       Date:  1986-06       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.